NDATOPICALCREAM
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANIQA (eflornithine hydrochloride) by AbbVie is clinical pharmacology. First approved in 2000.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANIQA is a topical cream containing eflornithine hydrochloride, a small-molecule ornithine decarboxylase inhibitor approved in 2000 for reducing unwanted facial hair growth in women. It works by slowing hair growth through inhibition of a key enzyme in the hair follicle, offering a non-invasive alternative to hair removal methods.
LOE Approaching
As an LOE-approaching product with moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension and cost-optimization rather than growth expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VANIQA as an LOE-approaching product offers limited growth career trajectory but strong operational and defensive strategy experience. This role suits professionals focused on cost optimization, market access negotiations, and lifecycle extension—skills valuable for managing mature portfolios.
Brand ManagerField Sales Representative
Worked on VANIQA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.